Myeloid Cell Diversity and Impact of Metabolic Cues During Atherosclerosis

Overview

Journal Immunometabolism

Date 2024 Dec 9

PMID 39649554

Authors

Alexandre Gallerand

Marion I Stunault

Johanna Merlin

Rodolphe R Guinamard

Laurent Yvan-Charvet

Stoyan Ivanov

Affiliations

Soon will be listed here.

Abstract

Myeloid cells are key contributors to tissue, immune and metabolic homeostasis and their alteration fuels inflammation and associated disorders such as atherosclerosis. Conversely, in a classical chicken-and-egg situation, systemic and local metabolism, together with receptor-mediated activation, regulate intracellular metabolism and reprogram myeloid cell functions. Those regulatory loops are notable during the development of atherosclerotic lesions. Therefore, understanding the intricate metabolic mechanisms regulating myeloid cell biology could lead to innovative approaches to prevent and treat cardiovascular diseases. In this review, we will attempt to summarize the different metabolic factors regulating myeloid cell homeostasis and contribution to atherosclerosis, the most frequent cardiovascular disease.

References

Bjornheden T, Levin M, Evaldsson M, Wiklund O . Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol. 1999; 19(4):870-6. DOI: 10.1161/01.atv.19.4.870. View

Aratani Y . Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys. 2018; 640:47-52. DOI: 10.1016/j.abb.2018.01.004. View

Nathan C . Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006; 6(3):173-82. DOI: 10.1038/nri1785. View

Otsuka F, Joner M, Prati F, Virmani R, Narula J . Clinical classification of plaque morphology in coronary disease. Nat Rev Cardiol. 2014; 11(7):379-89. DOI: 10.1038/nrcardio.2014.62. View

Krawczyk C, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis R . Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood. 2010; 115(23):4742-9. PMC: 2890190. DOI: 10.1182/blood-2009-10-249540. View

Rodriguez-Espinosa O, Rojas-Espinosa O, Moreno-Altamirano M, Lopez-Villegas E, Sanchez-Garcia F . Metabolic requirements for neutrophil extracellular traps formation. Immunology. 2014; 145(2):213-24. PMC: 4427386. DOI: 10.1111/imm.12437. View

Ridker P, MacFadyen J, Everett B, Libby P, Thuren T, Glynn R . Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2017; 391(10118):319-328. DOI: 10.1016/S0140-6736(17)32814-3. View

Doran A, Yurdagul Jr A, Tabas I . Efferocytosis in health and disease. Nat Rev Immunol. 2019; 20(4):254-267. PMC: 7667664. DOI: 10.1038/s41577-019-0240-6. View

Wan W, Lionakis M, Liu Q, Roffe E, Murphy P . Genetic deletion of chemokine receptor Ccr7 exacerbates atherogenesis in ApoE-deficient mice. Cardiovasc Res. 2012; 97(3):580-8. PMC: 3567784. DOI: 10.1093/cvr/cvs349. View

10.

Doring Y, Drechsler M, Wantha S, Kemmerich K, Lievens D, Vijayan S . Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. Circ Res. 2012; 110(8):1052-6. DOI: 10.1161/CIRCRESAHA.112.265868. View

11.

Kahlenberg J, Carmona-Rivera C, Smith C, Kaplan M . Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol. 2012; 190(3):1217-26. PMC: 3552129. DOI: 10.4049/jimmunol.1202388. View

12.

Gu L, Okada Y, Clinton S, Gerard C, Sukhova G, Libby P . Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998; 2(2):275-81. DOI: 10.1016/s1097-2765(00)80139-2. View

13.

van Leeuwen M, Gijbels M, Duijvestijn A, Smook M, van de Gaar M, Heeringa P . Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/- mice. Arterioscler Thromb Vasc Biol. 2007; 28(1):84-9. DOI: 10.1161/ATVBAHA.107.154807. View

14.

Kierszenbaum F, Wirth J, McCann P, SJOERDSMA A . Impairment of macrophage function by inhibitors of ornithine decarboxylase activity. Infect Immun. 1987; 55(10):2461-4. PMC: 260730. DOI: 10.1128/iai.55.10.2461-2464.1987. View

15.

Williams J, Martel C, Potteaux S, Esaulova E, Ingersoll M, Elvington A . Limited Macrophage Positional Dynamics in Progressing or Regressing Murine Atherosclerotic Plaques-Brief Report. Arterioscler Thromb Vasc Biol. 2018; 38(8):1702-1710. PMC: 6202234. DOI: 10.1161/ATVBAHA.118.311319. View

16.

Thwe P, Pelgrom L, Cooper R, Beauchamp S, Reisz J, DAlessandro A . Cell-Intrinsic Glycogen Metabolism Supports Early Glycolytic Reprogramming Required for Dendritic Cell Immune Responses. Cell Metab. 2017; 26(3):558-567.e5. PMC: 5657596. DOI: 10.1016/j.cmet.2017.08.012. View

17.

Sluimer J, Gasc J, van Wanroij J, Kisters N, Groeneweg M, Sollewijn Gelpke M . Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol. 2008; 51(13):1258-65. DOI: 10.1016/j.jacc.2007.12.025. View

18.

Bischoff E, Daige C, Petrowski M, Dedman H, Pattison J, Juliano J . Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice. J Lipid Res. 2010; 51(5):900-6. PMC: 2853457. DOI: 10.1194/jlr.M900096. View

19.

Khan M, Palaniyar N . Transcriptional firing helps to drive NETosis. Sci Rep. 2017; 7:41749. PMC: 5296899. DOI: 10.1038/srep41749. View

20.

Covarrubias A, Aksoylar H, Yu J, Snyder N, Worth A, Iyer S . Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. Elife. 2016; 5. PMC: 4769166. DOI: 10.7554/eLife.11612. View